The different faces of renal angiomyolipomas on radiologic imaging: a pictorial review

Thiravit, Shanigarn; Teerasamit, Wanwarang; Thiravit, Phakphoom

doi:10.1259/bjr.20170533

Cited by 20 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Instead, we focused on ccRCC as it is the most predominant RCC subtype . We also did not consider other nontumor renal pathologies, such as angiomyolipoma (AML), although recent evidence suggests that AML can be safely diagnosed by imaging . The use of histology as the diagnostic gold standard represents another limitation.…”

Section: Discussionmentioning

confidence: 99%

“…3 We also did not consider other nontumor renal pathologies, such as angiomyolipoma (AML), although recent evidence suggests that AML can be safely diagnosed by imaging. 46 The use of histology as the diagnostic gold standard represents another limitation. Pathologists frequently struggle to accurately classify SRMs (pT1a, ≤4 cm); however, recent reports suggest that renal biopsy is a safe and accurate technique for diagnosis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Searching for prognostic biomarkers for small renal masses in the urinary proteome

Meo

Batruch

Brown

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is frequently diagnosed incidentally as an early‐stage small renal mass (SRM; pT1a, ≤4 cm). Overtreatment of patients with benign or clinically indolent SRMs is increasingly common and has resulted in a recent shift in treatment recommendations. There are currently no available biomarkers that can accurately predict clinical behavior. Therefore, we set out to identify early biomarkers of RCC progression. We employed a quantitative label‐free liquid chromatography coupled to tandem mass spectrometry (LC‐MS/MS) proteomics approach and targeted parallel‐reaction monitoring to identify and validate early, noninvasive urinary biomarkers for RCC‐SRMs. In total, we evaluated 115 urine samples, including 33 renal oncocytoma (≤4 cm) cases, 30 progressive and 26 nonprogressive clear cell RCC (ccRCC)‐SRM cases, in addition to 26 healthy controls. We identified six proteins, which displayed significantly elevated expression in clear cell RCC‐SRMs (ccRCC‐SRMs) relative to healthy controls. Proteins C12ORF49 and EHD4 showed significantly elevated expression in ccRCC‐SRMs compared to renal oncocytoma (≤4 cm). Additionally, proteins EPS8L2, CHMP2A, PDCD6IP, CNDP2 and CEACAM1 displayed significantly elevated expression in progressive relative to nonprogressive ccRCC‐SRMs. A two‐protein signature (EPS8L2 and CCT6A) showed significant discriminatory ability (areas under the curve: 0.81, 95% CI: 0.70–0.93) in distinguishing progressive from nonprogressive ccRCC‐SRMs. Patients (Stage I–IV) with EPS8L2 and CCT6A mRNA alterations showed significantly shorter overall survival (p = 1.407 × 10−6) compared to patients with no alterations. Our in‐depth proteomic analysis identified novel biomarkers for early‐stage RCC‐SRMs. Pretreatment characterization of urinary proteins may provide insight into early RCC progression and could potentially help assign patients to appropriate management strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Searching for prognostic biomarkers for small renal masses in the urinary proteome

Meo

Batruch

Brown

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…However, recent evidence suggests that angiomyolipoma can be safely diagnosed by imaging. 40 The use of histology as the gold standard of SRM diagnosis represents another limitation. Pathologists frequently struggle to accurately classify incidentally detected SRMs (pT1a; 4 cm); however, recent evidence suggests that renal biopsy is a safe and accurate technique for diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Identification of Prognostic Biomarkers in the Urinary Peptidome of the Small Renal Mass

Meo

Batruch

Brown

et al. 2019

The American Journal of Pathology

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is often diagnosed incidentally as a small renal mass (SRM; pT1a, 4 cm). Increasing concerns surrounding the overtreatment of patients with benign or clinically silent SRMs has resulted in a recent shift in treatment recommendations, especially in elderly and infirm patients. There are currently no biomarkers that can predict progression. We used a quantitative label-free liquid chromatographyetandem mass spectrometry peptidomics approach and targeted parallel-reaction monitoring to identify early, noninvasive diagnostic and prognostic biomarkers for early-stage RCC-SRMs. In total, 115 urine samples, including 33 renal oncocytoma (4 cm) cases, 30 progressive and 26 nonprogressive clear cell RCC-SRM cases, and 26 healthy controls were evaluated. Nine endogenous peptides that displayed significantly elevated expression in clear cell RCC-SRMs relative to healthy controls were identified. Peptides NVINGGSHAGNKLAMQEF, VNVDEVGGEALGRL, and VVAGVANALAHKYH showed significantly elevated expression in clear cell RCC-SRMs relative to renal oncocytoma. Additionally, peptides SHTSDSDVPSGVTEVVVKL and IVDNNILFLGKVNRP displayed significantly elevated expression in progressive relative to nonprogressive clear cell RCC-SRMs. Peptide SHTSDSDVPSGVTEVVVKL showed the most significant discriminatory utility (area under the curve, 0.76; 95% CI, 0.62e0.90; P Z 0.0027). Patients with elevated SHTSDSDVPSGVTEVVVKL expression had significantly shorter overall survival (hazard ratio, 4.13; 95% CI, 1.09e15.65; P Z 0.024) compared to patients with low expression. Pretreatment characterization of urinary peptides can provide insight into early RCC progression and may aid clinical decision-making and improve disease management.

show abstract

“…Renal oncocytoma is the most prevalent benign lesion of the kidney, and recent evidence suggests that renal AML can be safely diagnosed by imaging [ 258 ].…”

Section: Mirnas As Diagnostic Biomarkers For Oncocytomamentioning

confidence: 99%

Renal Oncocytoma: The Diagnostic Challenge to Unmask the Double of Renal Cancer

Trevisani

Floris

Minnei

et al. 2022

IJMS

View full text Add to dashboard Cite

Renal oncocytoma represents the most common type of benign neoplasm that is an increasing concern for urologists, oncologists, and nephrologists due to its difficult differential diagnosis and frequent overtreatment. It displays a variable neoplastic parenchymal and stromal architecture, and the defining cellular element is a large polygonal, granular, eosinophilic, mitochondria-rich cell known as an oncocyte. The real challenge in the oncocytoma treatment algorithm is related to the misdiagnosis due to its resemblance, at an initial radiological assessment, to malignant renal cancers with a completely different prognosis and medical treatment. Unfortunately, percutaneous renal biopsy is not frequently performed due to the possible side effects related to the procedure. Therefore, the majority of oncocytoma are diagnosed after the surgical operation via partial or radical nephrectomy. For this reason, new reliable strategies to solve this issue are needed. In our review, we will discuss the clinical implications of renal oncocytoma in daily clinical practice with a particular focus on the medical diagnosis and treatment and on the potential of novel promising molecular biomarkers such as circulating microRNAs to distinguish between a benign and a malignant lesion.

show abstract

The different faces of renal angiomyolipomas on radiologic imaging: a pictorial review

Cited by 20 publications

References 10 publications

Searching for prognostic biomarkers for small renal masses in the urinary proteome

Searching for prognostic biomarkers for small renal masses in the urinary proteome

Identification of Prognostic Biomarkers in the Urinary Peptidome of the Small Renal Mass

Renal Oncocytoma: The Diagnostic Challenge to Unmask the Double of Renal Cancer

Contact Info

Product

Resources

About